Evidence map›Paper›PMID 32663409›Full record

ArticleAmerican journal of respiratory and critical care medicine2020

Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2.

Yu Zhao, Zixian Zhao, Yujia Wang, Yueqing Zhou, Yu Ma, Wei Zuo

Erratum issuedOpen access · hybridAbstract readLetter
In one paragraph

Article in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 687 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
687citing papers in PubMed, 3 pooled it
22.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

687 citing papers in PubMed, 3 syntheses or guidelines pooled it, 950 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2022
    Pooled it
  4. Effect of ArtemiC in patients with COVID-19: A Phase II prospective study.Journal of cellular and molecular medicine · 2022
    Trial
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

627 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yu ZhaoTongji University Shanghai, China.
Zixian ZhaoTongji University Shanghai, China.
Yujia WangTongji University Shanghai, China.
Yueqing ZhouTongji University Shanghai, China.
Yu MaRegend Therapeutics Suzhou, China.
Wei ZuoTongji University Shanghai, China.ORCID 0000-0002-4460-0337
Shanghai East Hospital · CNFirst Affiliated Hospital of Guangzhou Medical University · CNRegend Therapeutics (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BetacoronavirusGene Expression RegulationCoronavirus InfectionsCOVID-19HumansPandemicsPeptidyl-Dipeptidase APneumonia, ViralRNASARS-CoV-2Peptidyl-Dipeptidase ARNA

Identifiers

PMID32663409
PMCPMC7462411
OpenAlexW3043002108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.